Congress mandates pediatric cancer studies for adult drugs, extends pharma voucher program
S. 3302 — Mikaela Naylon Give Kids a Chance Act of 2025 · Filed by Markwayne Mullin (R-OK) · 37 cosponsors · Introduced Dec 2, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal drug-approval rules to require pharmaceutical companies developing molecularly targeted cancer drugs to conduct pediatric studies as a condition of adult approval. It also extends the 'priority review voucher' program—which gives companies expedited FDA review in exchange for developing rare pediatric disease treatments—through 2030, and mandates congressional reports on whether these incentives actually produce new pediatric cancer and rare-disease drugs.
Why we flagged it
The bill's core mechanism is a regulatory requirement for pediatric cancer studies plus an extension of a tradeable FDA voucher program. Both are designed to incentivize pharmaceutical development for pediatric indications, not a general public-health mandate or restriction.
What the text implies
- The priority review voucher is tradeable and may be sold to large pharmaceutical firms, concentrating regulatory benefits among companies with capital to acquire vouchers rather than those developing the treatments.
- The 3-year implementation delay allows industry to prepare and potentially structure applications to minimize pediatric study burdens, reducing the practical impact of the pediatric cancer requirement.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies developing molecularly targeted cancer drugs; companies acquiring priority review vouchers; large-cap pharma firms with capital to invest in pediatric oncology programs